Asia TIDES®– Oligonucleotide and Peptide Research, Technology and Product Development

Asia TIDES®– Oligonucleotide and Peptide

Research, Technology and Product Development
February 28 – March 1, 2012, Sheraton Miyako Hotel, Tokyo, Japan

 

www.IBCLifeSciences.com/AsiaTIDES

 

The only event in Asia with comprehensive updates on therapeutics in development from major big pharma, biotech and academic scientists worldwide

 

AsiaTIDES continues to be the premier forum to get a comprehensive update, meet key players and increase your knowledge of the oligonucleotide- and peptide-based therapeutics fields.

 

The faculty list for the 2012 program is the strongest yet, with more representation from big pharma than ever before. Hear new data and strategic perspectives from Merck, Genzyme, and GlaxoSmithKline, including three presentations from Glaxo on a peptide project and their assessments of both the oligo and peptide landscape. Plus hear from Isis, Novo Nordisk, Ipsen, Quark, Alnylam, Santaris, Tekmira and a host of other important companies you need to follow to stay abreast of this field.

 

Keynote Presentations

Clinical Development of Mipomersen, an Antisense Second-Generation Oligonucleotide Targeting Apolipoprotein B

Tejdip Singh, M.D. Medical Director, Global Patient Safety and Risk Management, Genzyme Corporation, USA

 

Oligonucleotide and Delivery Platform Optimization Strategies for siRNA Drug Development

Laura Sepp-Lorenzino, Ph.D. Senior Director, RNA Therapeutics, Merck & Co., Inc., USA

 

Recent Advances in Routes of Delivery for Peptide Pharmaceuticals

Nozer Mehta, Ph.D. Vice President, R&D, UniGene Laboratories, Inc., USA

 

Overview of Peptide Therapeutics and Vaccines in Development

Yuji Heike, M.D., Ph.D. Hemato-Oncology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Japan

 

Evolution and Development of GLP-1 Based Therapeutics

Andrew A. Young, M.D., Ph.D. Vice President, Head, Enterendocrine Biology, GlaxoSmithKline, USA

 

A Pivotal Year for Oligonucleotide Therapeutics

Arthur A. Levin, Ph.D. Chief Development Officer, Santaris A/S, USA and Denmark

 

RaPID Selection of a New Class of Peptide Drug Leads against Various Therapeutic Targets

Hiroaki Suga, Ph.D. Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan

 

• Regulatory Updates: Preclinical Safety Assessment of Oligonucleotides and Peptides including Reports from JPMA and the Oligonucleotide Safety Working Group on ICH S6 and Off Target Effects

• miRNA, Oligonucleotides, Peptides and Peptide Vaccines: Updates on therapeutic candidates in preclinical and clinical development

• Manufacturing and analytical development strategies to speed process development

• Formulation and delivery updates to help you gauge product marketability

 

In-Depth Tutorials to Increase your Knowledge:

• Technical and Regulatory Aspects of Peptide Specifications and Characterization: From Preclinical through to Market Application

• Strategies and Approaches for in vivo Delivery of Oligonucleotides

 

FOR MORE INFORMATION:

PHONE:+65 6508 2401

FAX:+ 65 6508 2407

E- MAIL: register@ibcasia.com.sg

 

WEB: www.IBCLifeSciences.com/AsiaTIDES